Cargando…

394 Desensitization Protocol to Methotrexate

BACKGROUND: A 17 year old patient was referred to Allergy outpatient clinic with history of recent anaphylaxis (wheezing, breathlessness, nausea, vomit and hypotension) to methotrexate (MTX) during the induction treatment of ALL L2. The diagnostic confirmation consisted in a skin test, with a positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Maya, Jonathan, del Rio, Blanca, Morales, Alexander, Rosas-Vargas, Miguel Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513022/
http://dx.doi.org/10.1097/01.WOX.0000412157.09242.5f
_version_ 1782251857275518976
author Maya, Jonathan
del Rio, Blanca
Morales, Alexander
Rosas-Vargas, Miguel Angel
author_facet Maya, Jonathan
del Rio, Blanca
Morales, Alexander
Rosas-Vargas, Miguel Angel
author_sort Maya, Jonathan
collection PubMed
description BACKGROUND: A 17 year old patient was referred to Allergy outpatient clinic with history of recent anaphylaxis (wheezing, breathlessness, nausea, vomit and hypotension) to methotrexate (MTX) during the induction treatment of ALL L2. The diagnostic confirmation consisted in a skin test, with a positive response at 1:100 dilution. The case was discussed together with Pediatric Oncology service, and was agreed that MTX was necessary for the patient survival, because of that we performed the following desensitization protocol. OBJECTIVE: Evaluate the effect and safety of a desensitization protocol to methotrexate in an adolescent with acute lymphoblastic leukemia L2 (ALL L2) and allergy to methotrexate. METHODS: Desensitization protocol consisted in 2 phases. First phase consisted in premedication with hydrocortisone (IV) 1 mgkgdo, cetirizine (PO) 0.2 mgkgdo, chlorpheniramine (IV) 0.35 mgkgdo and montelukast (PO) 10 mgdo at 13, 7 and 1 hour prior to desensitization phase which consisted in an 8 hour scheme of IV infusion of 12 dilutions with increasing concentrations starting at 1:1,000,000 at 30 minutes intervals up to the full dose was completed. RESULTS: Patient was admitted to pediatric intensive care unit and was successfully desensitized, the full protocol was completed as expected, including pre-medication, the desensitization phase lasted 8 hours; at the second dilution (1:100,000) the patient presented nausea, requiring one extra dose of chlorpheniramine, no other adverse reactions were presented in the next 48 hours observation period. He was maintained with 50 mg/m(2) IV MTX weekly for the full anti-leukemia treatment duration (1–2 years) using the same protocol and stayed out of MTX-related adverse reactions. Today he is followed as an outpatient by our service. CONCLUSIONS: This 12 steps MTX-desensitization protocol was effective and safe. In selected cases of severe allergic reactions to chemotherapeutic agents there where no other equally effective treatment option available, desensitization is effective and safe.
format Online
Article
Text
id pubmed-3513022
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35130222012-12-21 394 Desensitization Protocol to Methotrexate Maya, Jonathan del Rio, Blanca Morales, Alexander Rosas-Vargas, Miguel Angel World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: A 17 year old patient was referred to Allergy outpatient clinic with history of recent anaphylaxis (wheezing, breathlessness, nausea, vomit and hypotension) to methotrexate (MTX) during the induction treatment of ALL L2. The diagnostic confirmation consisted in a skin test, with a positive response at 1:100 dilution. The case was discussed together with Pediatric Oncology service, and was agreed that MTX was necessary for the patient survival, because of that we performed the following desensitization protocol. OBJECTIVE: Evaluate the effect and safety of a desensitization protocol to methotrexate in an adolescent with acute lymphoblastic leukemia L2 (ALL L2) and allergy to methotrexate. METHODS: Desensitization protocol consisted in 2 phases. First phase consisted in premedication with hydrocortisone (IV) 1 mgkgdo, cetirizine (PO) 0.2 mgkgdo, chlorpheniramine (IV) 0.35 mgkgdo and montelukast (PO) 10 mgdo at 13, 7 and 1 hour prior to desensitization phase which consisted in an 8 hour scheme of IV infusion of 12 dilutions with increasing concentrations starting at 1:1,000,000 at 30 minutes intervals up to the full dose was completed. RESULTS: Patient was admitted to pediatric intensive care unit and was successfully desensitized, the full protocol was completed as expected, including pre-medication, the desensitization phase lasted 8 hours; at the second dilution (1:100,000) the patient presented nausea, requiring one extra dose of chlorpheniramine, no other adverse reactions were presented in the next 48 hours observation period. He was maintained with 50 mg/m(2) IV MTX weekly for the full anti-leukemia treatment duration (1–2 years) using the same protocol and stayed out of MTX-related adverse reactions. Today he is followed as an outpatient by our service. CONCLUSIONS: This 12 steps MTX-desensitization protocol was effective and safe. In selected cases of severe allergic reactions to chemotherapeutic agents there where no other equally effective treatment option available, desensitization is effective and safe. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3513022/ http://dx.doi.org/10.1097/01.WOX.0000412157.09242.5f Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Maya, Jonathan
del Rio, Blanca
Morales, Alexander
Rosas-Vargas, Miguel Angel
394 Desensitization Protocol to Methotrexate
title 394 Desensitization Protocol to Methotrexate
title_full 394 Desensitization Protocol to Methotrexate
title_fullStr 394 Desensitization Protocol to Methotrexate
title_full_unstemmed 394 Desensitization Protocol to Methotrexate
title_short 394 Desensitization Protocol to Methotrexate
title_sort 394 desensitization protocol to methotrexate
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513022/
http://dx.doi.org/10.1097/01.WOX.0000412157.09242.5f
work_keys_str_mv AT mayajonathan 394desensitizationprotocoltomethotrexate
AT delrioblanca 394desensitizationprotocoltomethotrexate
AT moralesalexander 394desensitizationprotocoltomethotrexate
AT rosasvargasmiguelangel 394desensitizationprotocoltomethotrexate